$1.56
4.29% day before yesterday
Nasdaq, Jul 11, 10:13 pm CET
ISIN
US17322U2078
Symbol
CTXR
Sector
Industry

Citius Pharmaceuticals Inc Stock price

$1.56
+0.55 54.46% 1M
-1.93 55.30% 6M
-2.44 61.00% YTD
-17.75 91.92% 1Y
-21.03 93.09% 3Y
-29.19 94.93% 5Y
-654.69 99.76% 10Y
-373.44 99.58% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.07 4.29%
ISIN
US17322U2078
Symbol
CTXR
Sector
Industry

Key metrics

Basic
Market capitalization
$17.4m
Enterprise Value
$17.4m
Net debt
positive
Cash
$30.0k
Shares outstanding
8.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1.1
EV/Sales
- | 1.1
EV/FCF
negative
P/B
0.3
Financial Health
Equity Ratio
60.1%
Return on Equity
-57.4%
ROCE
-60.0%
ROIC
-52.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $16.0m
EBITDA
- | -
EBIT
$-43.0m | $-29.5m
Net Income
$-43.1m | $-29.1m
Free Cash Flow
$-23.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-9.9% | 29.8%
Net Income
-15.4% | 27.5%
Free Cash Flow
22.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -182.2%
Free Cash Flow
-
More
EPS
$-5.0
FCF per Share
$-2.7
Short interest
12.6%
Employees
23
Rev per Employee
$0.0
Show more

Is Citius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Citius Pharmaceuticals Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Citius Pharmaceuticals Inc forecast:

Buy
78%
Hold
22%

Financial data from Citius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
20% 20%
-
- Research and Development Expense 12 12
10% 10%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -43 -43
10% 10%
-
Net Profit -43 -43
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Citius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Citius Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
4 days ago
CRANFORD, N.J.  , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that for 10 consecutive trading days, from June 20, 2025 to July 3, 2025, the closing bid price of the Company's common stock was at $1.00 per share or greater...
Neutral
PRNewsWire
25 days ago
CRANFORD, N.J. , June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a...
Neutral
PRNewsWire
about one month ago
$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J. , June 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today ...
More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office United States
CEO Leonard Mazur
Employees 23
Founded 2007
Website www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today